Hutchinson Capital Management CA increased its position in Novo Nordisk A/S (NYSE:NVO) by 0.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 506,898 shares of the company’s stock after buying an additional 4,081 shares during the period. Novo Nordisk A/S accounts for about 6.2% of Hutchinson Capital Management CA’s investment portfolio, making the stock its 3rd largest position. Hutchinson Capital Management CA’s holdings in Novo Nordisk A/S were worth $21,741,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in NVO. Proficio Capital Partners LLC increased its position in shares of Novo Nordisk A/S by 155.6% in the first quarter. Proficio Capital Partners LLC now owns 2,472 shares of the company’s stock worth $103,000 after buying an additional 1,505 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Novo Nordisk A/S by 167.8% in the first quarter. Tower Research Capital LLC TRC now owns 3,061 shares of the company’s stock worth $105,000 after buying an additional 1,918 shares during the last quarter. Parallel Advisors LLC increased its position in shares of Novo Nordisk A/S by 120.3% in the first quarter. Parallel Advisors LLC now owns 2,844 shares of the company’s stock worth $117,000 after buying an additional 1,553 shares during the last quarter. Advisory Services Network LLC bought a new position in shares of Novo Nordisk A/S during the first quarter worth approximately $127,000. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC increased its position in shares of Novo Nordisk A/S by 3,609.0% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,709 shares of the company’s stock worth $127,000 after buying an additional 3,609 shares during the last quarter. Hedge funds and other institutional investors own 6.40% of the company’s stock.

Novo Nordisk A/S (NYSE NVO) traded up 3.76% during midday trading on Friday, reaching $45.81. The company’s stock had a trading volume of 2,503,210 shares. Novo Nordisk A/S has a 52 week low of $30.89 and a 52 week high of $47.98. The stock has a market capitalization of $113.62 billion, a PE ratio of 18.74 and a beta of 0.63. The firm’s 50-day moving average price is $42.76 and its 200-day moving average price is $38.81.

The firm also recently declared an annual dividend, which will be paid on Tuesday, August 29th. Shareholders of record on Monday, August 21st will be paid a dividend of $0.336 per share. This represents a dividend yield of 1.07%. The ex-dividend date of this dividend is Friday, August 18th. This is a positive change from Novo Nordisk A/S’s previous annual dividend of $0.33. Novo Nordisk A/S’s dividend payout ratio is currently 36.00%.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.dailypolitical.com/2017/08/13/novo-nordisk-as-nysenvo-stake-raised-by-hutchinson-capital-management-ca.html.

Several equities research analysts have issued reports on the company. BidaskClub raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, June 15th. Zacks Investment Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $49.00 target price for the company in a research note on Wednesday, June 21st. Finally, TheStreet raised Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research note on Tuesday, May 2nd. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the company. Novo Nordisk A/S presently has an average rating of “Hold” and a consensus target price of $53.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.